Caribou Biosciences

CRBU

Market cap $217M

2.25 USD

-0.04

1.75%

At close Updated Apr 21, 4:00 PM EDT

Pre-market

After hours

2.29

+0.04

1.78%

1 day

-1.75%

5 days

5.14%

1 month

20.97%

3 months

51.01%

6 months

-20.77%

Year to date

41.51%

1 year

182.91%

5 years

-86.21%

10 years

-86.21%

About: Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Employees: 97

Healthcare Biotechnology